p.101 抽出テキスト

September 25, 2018 Circulation. 2018;138:e272–e391. DOI: 10.1161/CIR.0000000000000549 e372

CLINICAL STATEMENTS AND GUIDELINES S7.6-4.	 Mohsen A, Jimenez A, Hood RE, et al. Cardiac sarcoidosis: electro-

physiological outcomes on long-term follow-up and the role of the implantable cardioverter-defibrillator. J Cardiovasc Electrophysiol. 2014;25:171–6. S7.6-5.	 Schuller JL, Zipse M, Crawford T, et al. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012;23:925–9. S7.6-6.	 Coleman GC, Shaw PW, Balfour PC Jr, et al. Prognostic value of myocardial scarring on CMR in patients with cardiac sarcoidosis: a systematic review and meta-analysis. JACC Cardiovasc Imaging. 2016;10:411–20. S7.6-7.	 Murtagh G, Laffin LJ, Beshai JF, et al. Prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9:e003738. S7.6-8.	 Crawford T, Mueller G, Sarsam S, et al. Magnetic resonance imaging for identifying patients with cardiac sarcoidosis and preserved or mildly reduced left ventricular function at risk of ventricular arrhythmias. Circ Arrhythm Electrophysiol. 2014;7:1109–15. S7.6-9.	 Greulich S, Deluigi CC, Gloekler S, et al. CMR imaging predicts death and other adverse events in suspected cardiac sarcoidosis. JACC Cardiovasc Imaging. 2013;6:501–11. S7.6-10.	 Blankstein R, Osborne M, Naya M, et al. Cardiac positron emission tomography enhances prognostic assessments of patients with suspected cardiac sarcoidosis. J Am Coll Cardiol. 2014;63:329–36. S7.6-11.	 Aizer A, Stern EH, Gomes JA, et al. Usefulness of programmed ventricular stimulation in predicting future arrhythmic events in patients with cardiac sarcoidosis. Am J Cardiol. 2005;96:276–82. S7.6-12.	 Mehta RH, Starr AZ, Lopes RD, et al. Incidence of and outcomes associated with ventricular tachycardia or fibrillation in patients undergoing primary percutaneous coronary intervention. JAMA. 2009;301:1779–89. S7.6-13.	 Takaya Y, Kusano KF, Nakamura K, et al. Outcomes in patients with high-degree atrioventricular block as the initial manifestation of cardiac sarcoidosis. Am J Cardiol. 2015;115:505–9. S7.6-14.	 Naruse Y, Sekiguchi Y, Nogami A, et al. Systematic treatment approach to ventricular tachycardia in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2014;7:407–13. S7.6-15.	 Segawa M, Fukuda K, Nakano M, et al. Time course and factors correlating with ventricular tachyarrhythmias after introduction of steroid therapy in cardiac sarcoidosis. Circ Arrhythm Electrophysiol. 2016;9:e003353. S7.6-16.	 Yodogawa K, Seino Y, Ohara T, et al. Effect of corticosteroid therapy on ventricular arrhythmias in patients with cardiac sarcoidosis. Ann Noninvasive Electrocardiol. 2011;16:140–7. S7.6-17.	 Birnie DH, Sauer WH, Bogun F, et al. HRS expert consensus statement on the diagnosis and management of arrhythmias associated with cardiac sarcoidosis. Heart Rhythm. 2014;11:1305–23. S7.6-18.	 Mehta D, Mori N, Goldbarg SH, et al. Primary prevention of sud-

den cardiac death in silent cardiac sarcoidosis: role of programmed ventricular stimulation. Circ Arrhythm Electrophysiol. 2011;4:43–8.

7.6.1 Other Infiltrative Cardiomyopathies

S7.6.1-1.	 Lubitz SA, Goldbarg SH, Mehta D, Sudden cardiac death in infiltrative cardiomyopathies: sarcoidosis, scleroderma, amyloidosis, hemachromatosis. Prog Cardiovasc Dis. 2008;51:58–73. S7.6.1-2.	 Kristen AV, Dengler TJ, Hegenbart U, et al. Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm. 2008;5:235–40. S7.6.1-3.	 Sperry BW, Ikram A, Hachamovitch R, et al. Efficacy of chemotherapy for light-chain amyloidosis in patients presenting with symptomatic heart failure. J Am Coll Cardiol. 2016;67:2941–8. S7.6.1-4.	 Varr BC, Zarafshar S, Coakley T, et al. Implantable cardioverter-

defibrillator placement in patients with cardiac amyloidosis. Heart Rhythm. 2014;11:158–62.

7.7 Heart Failure

7.7.1 HF With Reduced Ejection Fraction

S7.7.1-1.	 Frohlich GM, Holzmeister J, Hubler M, et al. Prophylactic implantable

cardioverter defibrillator treatment in patients with end-stage heart failure awaiting heart transplantation. Heart. 2013;99:1158–65. S7.7.1-2.	 Kao AC, Krause SW, Handa R, et al. Wearable defibrillator use in

heart failure (WIF): results of a prospective registry. BMC Cardiovasc Disord. 2012;12:123. S7.7.1-3.	 Opreanu M, Wan C, Singh V, et al. Wearable cardioverter-defibrillator as a bridge to cardiac transplantation: a national database analysis. J Heart Lung Transplant. 2015;34:1305–49. S7.7.1-4.	 Sandner SE, Wieselthaler G, Zuckermann A, et al. Survival benefit of the implantable cardioverter-defibrillator in patients on the waiting list for cardiac transplantation. Circulation. 2001;104:171–6. S7.7.1-5.	 Vakil K, Duval S, Cogswell R, et al. Impact of implantable cardioverter-defibrillators on waitlist mortality among patients awaiting heart transplantation. An UNOS/OPTN Analysis. JACC Clin Electrophysiol. 2017;3:33–40. S7.7.1-6.	 Packer DL, Prutkin JM, Hellkamp AS, et al. Impact of implantable cardioverter-defibrillator, amiodarone, and placebo on the mode of death in stable patients with heart failure: analysis from the sudden cardiac death in heart failure trial. Circulation. 2009;120:2170–6. S7.7.1-7.	 MERIT-HF Study Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet. 1999;353:2001–7. S7.7.1-8.	 Luu M, Stevenson WG, Stevenson LW, et al. Diverse mechanisms of unexpected cardiac arrest in advanced heart failure. Circulation. 1989;80:1675–80. S7.7.1-9.	 Narang R, Cleland JG, Erhardt L, et al. Mode of death in chronic heart failure. A request and proposition for more accurate classification. Eur Heart J. 1996;17:1390–403. S7.7.1-10.	Bonet S, Agusti A, Arnau JM, et al. Beta-adrenergic blocking agents in heart failure: benefits of vasodilating and non-vasodilating agents according to patients’ characteristics: a meta-analysis of clinical trials. Arch Intern Med. 2000;160:621–7. S7.7.1-11.	Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309–21. S7.7.1-12.	Desai AS, McMurray JJ, Packer M, et al. Effect of the angiotensinreceptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J. 2015;36:1990–7. S7.7.1-13.	Cleland JG, Daubert JC, Erdmann E, et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med. 2005;352:1539–4. S7.7.1-14.	Tomaselli GF, Zipes DP, What causes sudden death in heart failure? Circ Res. 2004;95:754–63. S7.7.1-15.	Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;97:155–60. S7.7.1-16.	Gloschat CR, Koppel AC, Aras KK, et al. Arrhythmogenic and metabolic remodelling of failing human heart. J Physiol. 2016;594:3963–80. S7.7.1-17.	Vakil K, Kazmirczak F, Sathnur N, et al. Implantable cardioverter-

defibrillator use in patients with left ventricular assist devices: a systematic review and meta-analysis. JACC Heart Fail. 2016;4:772–9.

7.7.2 HF With Preserved Ejection Fraction

S7.7.2-1.	 Owan TE, Hodge DO, Herges RM, et al. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251–9. S7.7.2-2.	 Adabag S, Smith LG, Anand IS, et al. Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail. 2012;18:749–54. S7.7.2-3.	 Massie BM, Carson PE, McMurray JJ, et al. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456–67. S7.7.2-4.	 Yusuf S, Pfeffer MA, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and preserved leftventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777–81. S7.7.2-5.	 Pitt B, Pfeffer MA, Assmann SF, et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370: 1383–92. S7.7.2-6.	 Al-Khatib SM, Shaw LK, O’Connor C, et al. Incidence and predictors of sudden cardiac death in patients with diastolic heart failure. J Cardiovasc Electrophysiol. 2007;18:1231–5. S7.7.2-7.	 Gatzoulis MA, Till JA, Somerville J, et al. Mechanoelectrical interac-

tion in tetralogy of Fallot. QRS prolongation relates to right ventricular size and predicts malignant ventricular arrhythmias and sudden death. Circulation. 1995;92:231–7.

Downloaded from http://ahajournals.org by on October 7, 2026